摘要
羧肽酶G2是一种通过将甲氨蝶呤转化为非毒性代谢物进而降低血清甲氨蝶呤浓度的细菌酶。将羧肽酶G2应用于经标准解救治疗后的患者,患者血清MTX浓度快速下降。羧肽酶G2耐受性较好,毒副反应多为1、2级毒副反应,无需处置,是一种独特的甲氨蝶呤解毒剂,但其在临床中的应用仍有一定的局限性与争议。
Carboxypeptidases G2 is a bacterial enzyme that results in a decrease in plasma MTX concentrations by hydrolysis of MTX to inactive metabolites. Patients treated with carboxypeptidases G2 in addition to standard supportive care has a remarkable and rapid reduction in serum methotrexate level. Carboxypeptidases G2 is well tolerated,the most common adverse effects being typically grade 1 or 2 in severity and resolved without any intervention.However the clinical application of carboxypeptidases G2 still has some limitations and controversy.
出处
《实用药物与临床》
CAS
2016年第5期636-638,共3页
Practical Pharmacy and Clinical Remedies
关键词
羧肽酶G2
甲氨蝶呤
肾损害
Carboxypeptidase G2
Methotrexate
Renal damage
